Compare Moderna, Inc. (MRNA) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Remitly Global Inc — how do they compare? Moderna, Inc. trades at $196.71 (market cap $78.44B), while Remitly Global Inc trades at $23.5 (market cap $4.85B). The key difference: Moderna, Inc. is far larger — about 16.2× Remitly Global Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Remitly Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Remitly Global Inc for 53 Days on average.
| MRNA | RELY | |
|---|---|---|
Market Cap | $78.44B | $4.85B |
Volume | 14,597,511 | 2,599,081 |
Sector | Health | Technology |
52-Week High | $203.46 | $26.92 |
52-Week Low | $22.36 | $12.20 |
Typical Hold Time | 59 Days | 53 Days |
Enterprise Value | $74.59B | $4.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
RELY trades at $23.52, up 1.38% today, with a bullish technical signal from moving averages. The company shows strong fundamental momentum, with revenue growing from $654M in 2022 to $1.64B in 2025 and turning profitable with a net income of $67.93M. Recent Q2 2026 earnings beat expectations with EPS of $0.93 versus $0.12 expected, and active customers surpassed 10 million. Positive cash flow trends and a partnership with Etsy highlight operational strength and growth initiatives.
The outlook for RELY is positive, supported by accelerating revenue growth, expanding profit margins, and strong analyst consensus with a $30.50 price target. Key risks include reliance on continued customer expansion, competitive pressures in digital payments, and market volatility. The stock presents an opportunity for growth investors given its earnings beats and bullish institutional sentiment, though execution on growth targets remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
